ID   Hep-G2/BGAL
AC   CVCL_EQ66
DR   cancercelllines; CVCL_EQ66
DR   GEO; GSM138625
DR   GEO; GSM138626
DR   GEO; GSM138627
DR   Wikidata; Q54882788
RX   PubMed=17157261;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Transfected with: UniProtKB; P00722; Escherichia coli lacZ.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 05-10-23; Version: 14
//
RX   PubMed=17157261; DOI=10.1016/j.molcel.2006.10.012;
RA   Gaillard S., Grasfeder L.L., Haeffele C.L., Lobenhofer E.K., Chu T.-M.,
RA   Wolfinger R., Kazmin D., Koves T.R., Muoio D.M., Chang C.-Y.,
RA   McDonnell D.P.;
RT   "Receptor-selective coactivators as tools to define the biology of
RT   specific receptor-coactivator pairs.";
RL   Mol. Cell 24:797-803(2006).
//